Shares in Sarepta Therapeutics (Nasdaq: SRPT) were up 12% at lunchtime on Thursday, after the RNA therapy specialist announced a $30 million deal with Lacerta Therapeutics which added three CNS gene therapies to its pipeline.
The deal with Lacerta, a University of Florida spin-out with extensive adeno-associated vector (AAV) experience, will see Sarepta take charge of clinical operations for its partner's pipeline, which includes therapies for Pompe disease, glioblastoma and neurodegenerative proteinopathies.
"Today’s investment with Lacerta bolsters Sarepta’s position as a leader in precision genetic medicine"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze